Natalizumab in the treatment of multiple sclerosis.
Natalizumab is a monoclonal antibody, representing a new class of medication for treating relapsing multiple sclerosis (MS). Conventional treatments include interferons, glatiramer acetate and chemotherapies such as mitoxantrone and cyclophosphamide. These therapies offer only modest clinical benefits and are commonly not tolerated due to side effects. Natalizumab has been proven in large-scale, blinded, randomized, controlled trials to have an exceptional effect on preventing relapses, decreasing the risk of sustained progression of disability, and increasing the rate of disease-free patients over a 24-month period compared to placebo. These trials led to the speedy approval of natalizumab for treating relapsing MS, but its use was halted a few months after its induction after several cases of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease affecting the central nervous system. After a long deliberation by an FDA advisory panel and strong support from the MS community, natalizumab was reapproved with stringent restrictions including patient, provider and site registration. Natalizumab is now considered second-line therapy for patients who have failed first-line agents such as interferon or glatiramer acetate. As little is known about additional risk factors for PML and other potential infections, patients and providers must work together to carefully decide if potential benefits outweigh these rare but potentially devastating complications.
Brown
Brandon A
BA
Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Arch Pathol Lab Med. 2008 Nov;132(11):1830-4
18976024
N Engl J Med. 2005 Jul 28;353(4):362-8
15947080
Curr Med Res Opin. 2008 Sep;24(9):2679-90
18694542
N Engl J Med. 2006 Mar 2;354(9):899-910
16510744
Ann Intern Med. 1987 Jul;107(1):78-87
3296901
N Engl J Med. 2005 Jul 28;353(4):375-81
15947078
Neurology. 2009 Feb 3;72(5):396-401
18987352
Neurol Clin. 2008 Aug;26(3):833-54, x-xi
18657729
J Neurol. 2008 Nov;255(11):1815-7
19031099
Neurology. 2008 Mar 25;70(13 Pt 2):1150-1
17872364
Ann Neurol. 2009 Sep;66(3):403-6
19798640
Neurology. 1993 Apr;43(4):655-61
8469318
N Engl J Med. 2006 Mar 2;354(9):911-23
16510745
Ann Neurol. 2005 Dec;58(6):840-6
16283615
N Engl J Med. 2007 Jun 21;356(25):2622-9
17582072
Ann Neurol. 2006 May;59(5):743-7
16634029
Neurology. 1999 Aug 11;53(3):466-72
10449105
N Engl J Med. 2005 Jul 28;353(4):369-74
15947079
N Engl J Med. 2006 Mar 2;354(9):924-33
16510746
Neurology. 1983 Nov;33(11):1444-52
6685237
Neurology. 2009 Feb 3;72(5):402-9
19188571
Arch Neurol. 2007 Sep;64(9):1331-3
17846274
Intervirology. 1997;40(2-3):98-111
9450227
Mult Scler. 2009 Apr;15(4):525-6
19324985
Neurology. 2006 Sep 12;67(5):884-6
16966559
N Engl J Med. 2008 Feb 7;358(6):647-8
18256405
Curr Opin Neurol. 2004 Jun;17(3):365-70
15167073
N Engl J Med. 1983 Jan 27;308(4):173-80
6294517
Eur Arch Psychiatry Clin Neurosci. 1992;242(2-3):96-102
1486115
Arch Neurol. 2008 May;65(5):656-8
18474743
N Engl J Med. 1998 May 7;338(19):1345-51
9571254
Science. 2004 Nov 19;306(5700):1380-3
15550673
Arch Neurol. 2009 Feb;66(2):255-8
19204164